Siemens Healthineers AG (SMMNY)
| Market Cap | 51.90B -14.9% |
| Revenue (ttm) | 26.47B -0.9% |
| Net Income | 2.53B +1.9% |
| EPS | 2.26 +2.3% |
| Shares Out | n/a |
| PE Ratio | 20.53 |
| Forward PE | n/a |
| Dividend | 0.37 (1.59%) |
| Ex-Dividend Date | Feb 9, 2026 |
| Volume | 45,657 |
| Open | 23.36 |
| Previous Close | 22.87 |
| Day's Range | 23.11 - 23.36 |
| 52-Week Range | 19.20 - 28.92 |
| Beta | 0.83 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 5, 2026 |
About Siemens Healthineers AG
Siemens Healthineers AG, through its subsidiaries, develops, manufactures, and sells a range of diagnostic and therapeutic products and services to healthcare providers in Germany, the United States, rest of Europe, CIS, Africa, the Middle East, the Americas, the Asia Pacific, Japan, and China. It operates in four segments: Imaging, Diagnostics, Varian, and Advanced Therapies. The Imaging segment offers magnetic resonance imaging, computed tomography, X-ray, molecular imaging, and ultrasound systems; and software solutions to support the readin... [Read more]
Financial Performance
In fiscal year 2025, Siemens Healthineers AG's revenue was 23.38 billion, an increase of 4.53% compared to the previous year's 22.36 billion. Earnings were 2.14 billion, an increase of 10.40%.
Financial numbers in EUR Financial StatementsNews
How Siemens Healthineers is helping its international staff feel at home
Liza Follert, head of people attraction for Europe, the Middle East and Africa, explains how employee feedback has shaped Siemens Healthineers’ approach to inclusion, retention and recruitment
Truvian Health Announces Strategic Alliance with Siemens Healthineers to Advance the TruVerus™ Blood Testing Platform
SAN DIEGO--(BUSINESS WIRE)--Truvian Health Announces Strategic Alliance with Siemens Healthineers to Advance the TruVerus™ Blood Testing Platform.
Siemens Healthineers AG Transcript: Pre-close call
Q4 FY26 revenue growth is expected to accelerate in imaging and precision therapy, while diagnostics continues to decline. FX provides a revenue tailwind, but inflation and other costs weigh on earnings; FY27 inflation is expected to be offset by pricing and cost measures.
EQS-CMS: Siemens Healthineers AG: Release of a capital market information
EQS Post-admission Duties announcement: Siemens Healthineers AG / Disclosure pursuant to Art. 5 para. 1 lit. b), para. 3 of the Regulation (EU) No. 596/2014, as last amended by Regulation (EU) No. 202...
Sun Nuclear Announces Validated Adaptive QA Solution in Support of New Radiotherapy System, Accela, by Siemens Healthineers
MELBOURNE, Fla.--(BUSINESS WIRE)--Sun Nuclear, a Mirion Medical company, today announced that its AdaptCHECK™ software has been validated in collaboration with Siemens Healthineers technical experts a...
Siemens Healthineers, Novo Partner On MASLD, MASH Care
BRUSSELS (dpa-AFX) - Siemens Healthineers AG (SMMNY.PK, SHL.DE) and Novo, announced on Monday that they have agreed to work together to improve care for patients with metabolic dysfunction-associa...
Siemens Healthineers price target raised to EUR 46 from EUR 45 at Citi
Citi raised the firm’s price target on Siemens Healthineers (SMMNY) to EUR 46 from EUR 45 and keeps a Buy rating on the shares.
Siemens Healthineers price target raised to EUR 39 from EUR 38 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Siemens Healthineers (SMMNY) to EUR 39 from EUR 38 and keeps a Hold rating on the shares.
Siemens Healthineers AG Transcript: Status update
Q3 saw strong equipment orders and U.S. partnerships, but Diagnostics underperformed, leading to a lowered top-line outlook. Imaging revenue was delayed to Q4, which is expected to see accelerated growth. Spin-off and cost mitigation plans remain on track.
Siemens Healthineers price target raised to EUR 57.40 at JPMorgan
JPMorgan raised the firm’s price target on Siemens Healthineers (SMMNY) to EUR 57.40 from EUR 54.30 and keeps an Overweight rating on the shares.
Siemens Healthineers Q3 Earnings Call Highlights
Siemens Healthineers ETR: SHL lowered its fiscal 2026 revenue growth outlook after continued weakness in its Diagnostics business, while raising its adjusted earnings-per-share guidance to reflect tar...
Siemens Healthineers AG Earnings Call Transcript: Q3 2026
Q3 delivered strong equipment orders and solid growth in Imaging and Precision Therapy, but Diagnostics continued to decline, especially in China. Revenue guidance for FY2026 was lowered, while EPS guidance was raised due to tariff refunds. Robust order book and innovation support future growth.
Siemens Healthineers AG Earnings release: Q3 2026
Siemens Healthineers AG released its Q3 2026 earnings on July 31, 2026, summarizing the period's financial results.
Siemens Healthineers AG Slides: Q3 2026
Siemens Healthineers AG has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on July 31, 2026.
Siemens Healthineers Cuts Revenue Outlook on Diagnostics Weakness
The German supplier of medical equipment now expects fiscal-year revenue to grow by between 3.5% and 4.0% on a comparable basis, compared with 4.5% to 5% previously.
Siemens Healthineers cuts revenue forecast citing diagnostics weakness
Medical technology firm Siemens Healthineers cut its 2026 revenue growth forecast on Friday to a range of 3.5% to 4.0%, as China's procurement policy weighs on its diagnostics business.
Siemens Healthineers price target lowered to EUR 45 from EUR 55 at RBC Capital
RBC Capital lowered the firm’s price target on Siemens Healthineers (SMMNY) to EUR 45 from EUR 55 and keeps an Outperform rating on the shares.
Siemens Healthineers price target lowered to EUR 54.30 at JPMorgan
JPMorgan analyst David Adlington lowered the firm’s price target on Siemens Healthineers (SMMNY) to EUR 54.30 from EUR 55.80 and keeps an Overweight rating on the shares. Published first on…
Siemens Healthineers AG Transcript: Pre-close call
Q3 is expected to see mid-single digit Imaging growth, margin declines in key segments due to FX and inflation, and easing tariff headwinds. Diagnostics faces a smaller revenue drop and sequential margin improvement from cost actions.
Siemens Healthineers price target lowered to EUR 37 at Morgan Stanley
Morgan Stanley analyst Aisyah Noor lowered the firm’s price target on Siemens Healthineers (SMMNY) to EUR 37 from EUR 41 and keeps an Equal Weight rating on the shares. Published…
Siemens Healthineers AG Transcript: Status update
Imaging and advanced therapies showed strong momentum, while diagnostics faced significant headwinds in China but is expected to stabilize within two quarters. Strategic carve-out preparations for diagnostics are underway, with innovation and cost management supporting future growth.
AiM Medical Robotics Announces Collaboration Agreement with Siemens Healthineers to Advance MRI-Guided Robotic Neurosurgery
Worcester, MA, May 26, 2026 (GLOBE NEWSWIRE) -- AiM Medical Robotics, a leading developer of advanced robotic systems for MRI-guided neurosurgery, today announced a collaboration agreement with Siemen...
Siemens Healthineers price target lowered to EUR 55.80 at JPMorgan
JPMorgan lowered the firm’s price target on Siemens Healthineers (SMMNY) to EUR 55.80 from EUR 61.30 and keeps an Overweight rating on the shares.
Siemens Healthineers AG Earnings Call Transcript: Q2 2026
Imaging and precision therapy segments delivered strong growth and margin expansion in Q2 FY2026, offsetting significant FX and tariff headwinds, while Diagnostics faced revenue and margin declines due to China market challenges. FY2026 guidance was revised lower, but midterm double-digit EPS growth ambition remains intact.
Siemens Healthineers AG Slides: Q2 2026
Siemens Healthineers AG has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on May 7, 2026.